● A phase 3 prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single injection of Rexlemastrocel-Lalone or combined with hyaluronic acid in subjects with chronic discogenic lumbar back pain through 12months.
● Phase I, first in human, randomized, double-blind, vehicle and placebo-controlled, parallel group, multi-center study in subjects with single level, symptomatic lumbar intervertebral disc degeneration (>6 months) and unresponsive to conservative therapy for at least 3 months. The study will compare single intradiscal injections of high and low dose IDCT with two control groups (saline, Sodium Hyaluronate).

● A phase 3 randomized, double-blind, placebo and active controlled multicenter, parallel group study of the analgesic efficacy and safety of subcutaneous administration of Tanezumab in the adult subjects with chronic low backpain.
● A Phase 3 Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled , Parallel­ group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Uncontrolled Moderate to Severe Chronic Low back Pain and a History of Opioid-induced Constipation who require Around-the-clock Opioid therapy.
● A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting SubcutaneousInjectable Depot of Buprenorphine (CAM2038) in Subjects with Moderate to Severe Chronic Low Back Pain Currently Treated with Daily Opioid.
● A phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Moderate to Severe Chronic Low back pain and Osteoarthritis of Hip or Knee ( Study was put on hold in (2018 March).

● A phase 3, randomized, 16 weeks, multi-phase, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of Fulranumab as a monotherapy in subjects with signs and symptoms of osteoarthritis of the hip or knee. A phase 3 randomized, double-blind, placebo and active controlled multicenter, parallel group study of the analgesic efficacy and safety of subcutaneous administration of Tanezumab in the adult subjects with chronic low backpain.
● A phase 3 randomized, double-blind, double dummy, placebo controlled, active controlled, parallel group, multicenter trial of oxycodone/ naloxone controlled release tablet (OXN) to assess the analgesic efficacy (compared to placebo) and the management of opioid-induced constipation (compared to oxycodone controlled release tablets (OXY) in opioid experienced subjects with uncontrolled moderate to severechronic low back pain and a history of opioid- induced constipation who required around-the-clock opioid therapy.

● The SPD 489-322 A phase 3, multicenter, randomized, double-blind, parallel group, placebo- controlled, flexible dose titration, efficacy and safety study of SPD 489 incombination with an antidepressant in the treatment of adults with major depressive disorder with inadequate response to prospective treatment with an antidepressant(Sub-Investigator).
● The SPD 489-322 A phase3, open label, multicenter, 12-month extension safety and tolerability study of SPD 489 in combination with an antidepressant in the treatment of adults with major depressive disorder with residual symptoms of inadequate response following treatment with an anti-depressant(SI).

A Phase II a double blind, placebo controlled multicenter study of Sirukumab as adjunctive treatment to a monoaminergic antidepressant in adult with Major Depressive Disorder (SI).

● A multicenter, randomized double-blind, parallel-group, placebo-controlled studies evaluation the efficacy, safety, and pharmacokinetics of SAGE-547 injection in the treatment of adult female subjects with severe postpartum depression and adult female subjects with moderate postpartum depression. 547-PPD-202.
● A multicenter, double blind, placebo-controlled study evaluation the efficacy, safety, tolerability, and pharmacokinetics of Brexanolone in the treatment of adolescent female subjects with postpartum depression. Protocol Number: 547-PPD-304.